Kobayashi Pharmaceutical Co., Ltd.
KBYPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.93B
Close$
$19.88
49.6% downside
Current Fair Value
49.6% downsideOvervalued by 49.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.93 Billion |
|---|---|
| Enterprise Value | $-46,777,736,629.00 |
| Annual dividend | $0.66 |
| Dividend yield | 1.47% |
| Earnings per Share | $49.19 |
| Beta | 0.25 |
| Outstanding Shares | 74,338,621 |
Return
| Return on Equity | 0.81% |
|---|---|
| Return on Assets | 0.67% |
| Return on Invested Capital | 5.63% |
Valuation & Multiples
| P/E Ratio | 325.93 |
|---|---|
| PEG | -348.58 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 2.86 |
| Enterprise Value to EBIT | 40.16 |
| Enterprise Value to Net Income | -28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.15
Consensus analyst estimateRevenue Estimate
$230.22 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.41
Consensus analyst estimateRevenue Estimate
$286.70 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Kobayashi Pharmaceutical Co., Ltd.
3,731 employees
CEO: Norikazu Toyoda
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and international...